INFINITESIMAL, LLC

Biotech · Private

CellFab™: an automated platform for high-throughput single-cell transfection of induced pluripotent stem cells (iPSCs) using microelectroporation in a 96-well plate format, integrated with microscopy,

Grants
$1.6M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
1 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · A Force-controlled Probe Based Platform for Single-Cell Biomolecular Delivery$999,998
Federal grantDepartment of Health and Human Services · Phase II · A Force-controlled Probe Based Platform for Single-Cell Biomolecular Delivery$499,999
Federal grantDepartment of Health and Human Services · Phase I · High-throughput single-cell transfection system for gene editing and isogenic iPS cell line generation$149,470
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3046VIRONIKA LLC——
3047CASCADE THERAPEUTICS, INC.——
3048BACCHUS THERAPEUTICS INC——
3049INFINITESIMAL, LLC——
3050PROTEIN POTENTIAL LLC——
3051Alentis Therapeutics——
3052OLFA THERA, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 3

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.